NT 201

Phase 3Small molecule

MMerz Pharmaceuticals GmbH

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain InjuryActive, not recruiting

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain InjuryPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

NCT03992404

Q3 2027

Phase 3Active, not recruiting

Neuromuscular Agents

NCT07210463

Phase 3Active, not recruiting

Neuromuscular Agents

NCT07122193

Clinical

Trials by Indication[1]

Glabellar Frown Lines5 trials

NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00777803·381 enrolled

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Completed·MMerz North America, Inc.·Phase 3·NCT04594213·362 enrolled

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00694148·108 enrolled

Show 2 more trials

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Completed·MMerz Aesthetics GmbH·Phase 2·NCT03806933·241 enrolled

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

Completed·MMerz North America, Inc.·Phase 3·NCT04622254·368 enrolled

Treatment2 trials

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

Completed·MMerz North America, Inc.·Phase 1·NCT05784363·31 enrolled

A Study of NT 201 Doses in the Treatment of Platysma Prominence

Completed·MMerz Aesthetics GmbH·Phase 2·NCT05773053·73 enrolled

Neuromuscular Agents2 trials

A Phase 3, Randomized, Parallel-Group, Double-Blind, Multicenter Study Investigating the Safety and Efficacy of NT 201 Compared With Placebo in Adult Participants With Moderate to Severe Platysma Prominence in the United States

Active, not recruiting·MMerz North America, Inc.·Phase 3·NCT07122193·300 enrolled

A Phase 3, Randomized, Parallel-group, Double-blind, Multicenter Study Investigating the Safety and Efficacy of NT 201 Compared With Placebo in Adult Participants With Moderate to Severe Platysma Prominence in Europe

Active, not recruiting·MMerz Aesthetics GmbH·Phase 3·NCT07210463·300 enrolled

Cervical Dystonia1 trial

Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia

Completed·MMerz Pharmaceuticals GmbH·Phase 4·NCT00541905·82 enrolled

Intellectual disability1 trial

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT02270736·256 enrolled

3 more indications

Essential Tremor1 trial

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Completed·MMerz Pharmaceuticals GmbH·Phase 2·NCT04766723·78 enrolled

Blepharospasm1 trial

Blepharospasm Short Interval

Terminated·MMerz Pharmaceuticals GmbH·Phase 2·NCT00507637·8 enrolled

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury1 trial

Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment

Active, not recruiting·MMerz Pharmaceuticals GmbH·Phase 3·NCT03992404·603 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for NT 201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NT 201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NT 201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merz Pharmaceuticals GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMerz Pharmaceuticals GmbH

NT 201

Status by Indication[3][1]

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Glabellar Frown Lines5 trials

Treatment2 trials

Neuromuscular Agents2 trials

Cervical Dystonia1 trial

Intellectual disability1 trial

Essential Tremor1 trial

Blepharospasm1 trial

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury1 trial

References

Drug Info

Quick Facts

Related News